High variation of tioguanine absorption in patients with chronic active Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 2, 2003, Pages 183-189

  Deibert, P ^a   Dilger, K ^b   Fischer, C ^c   Hofmann, U ^c   Nauck, S ^a   Stoelben, S ^a   Kreisel, W ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Dr Falk Pharma GmbH   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; NUCLEOTIDE; TIOGUANINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; ANTI-INFLAMMATORY AGENTS; CROHN DISEASE; CROSS-OVER STUDIES; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; THIOGUANINE; TREATMENT OUTCOME;

EID: 0042629433     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01652.x     Document Type: Article

References (34)

1. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
2. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
3. Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105: 367-72.
4. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
5. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999; 94: 3248-53.
6. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-5.
7. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
8. Dubinsky MCM, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
9. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.
10. Cuffari C, Theoret Y, Latour S, et al. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
11. Achkar JP, Stevens T, Brzezinski A, et al. 6-thioguanine levels versus white blood counts in guiding 6-mercaptopurine and azathioprine therapy. Gastroenterology 2000; 95: A272 (Abstract).
12. Dubinsky MC, Hassard PV, Kam LY, et al. Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for '6-MP resistance'. Gastroenterology 2000; 118: A4926(Abstract).
13. Derijks L, De Jong DJ, Gilissen LP, et al. 6-thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15: 63-7.
14. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9.
15. Herrlinger KR, Kreisel W, Schwab M, et al. 6-thioguanine - efficacy and safety in chronic active Crohn's disease. Aliment Pharmacol Ther 2003; 17: 503-8.
16. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 266-72.
17. Lancaster DL, Patel N, Lennard L, et al. 6-thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br J Clin Pharmacol 2001; 51: 531-9.
18. Lennard L, Davies HA, Lilleyman JS. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 1993; 68: 186-90.
19. Lowe ES, Kitchen BJ, Erdmann G, et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. Cancer Chemother Pharmacol 2001; 47: 199-205.
20. Lancaster DL, Patel N, Lennard L, et al. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 2002; 50: 33-6.
21. Brox LW, Birkett L, Belch A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 1981; 6: 35-8.
22. Liliemark J, Pettersson B, Järnmark M, et al. On the cellular pharmacokinetics of 6-thioguanine in acute myelogenous leukemia. Leukemia Lymphoma 1991; 4: 271-6.
23. Elion GB, Callahan SW, Hitchings GH, et al. Experimental, clinical, and metabolic studies of thiopurines. Cancer Chemother Rep 1962; 16: 197-202.
24. LePage GA, Whitecar JP Jr. Pharmacology of 6-thioguanine in man. Cancer Res 1971; 31: 1627-31.
25. Kröplin T, Weyer N, Gutsche S, et al. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate. Eur J Clin Pharmacol 1998; 54: 265-71.
26. Krakoff IH. A difference between 6-mercaptopurine and thioguanine in man. Proc Am Assoc Cancer Res 1964; 5: 37.
27. Kovach JS, Rubin J, Creagan ET, et al. Phase I trial of parenteral 6-thioguanine given on 5 consecutive days. Cancer Res 1986; 46: 5959-62.
28. Kallinteri P, Antimisiaris SG. Solubility of drugs in the presence of gelatin: effect of drug lipophilicity and degree of ionization. Int J Pharm 2001; 221: 219-26.
29. Riad LE, Sawchuk RJ. Effect of polyethylene glycol 400 on the intestinal permeability of carbamazepine in the rabbit. Pharm Res 1991; 8: 491-7.
30. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 886-92.
31. Weitschies W, Karaus M, Cordini D, et al. Magnetic marker monitoring of disintegrating capsules. Eur J Pharm Sci 2001; 13: 411-6.
32. Konits PH, Egorin MJ, Van Echo DA, et al. Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 1982; 8: 199-203.
33. Kitchen BJ, Balis FM, Poplack DG, et al. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clin Cancer Res 1997; 3: 713-7.
34. Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009-14.